We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Xenetic Bio | LSE:XEN | London | Ordinary Share | GB00B08NWV55 | ORD 0.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
05/7/2018 17:42 | Tiny free float suggests huge daily increases to be followed by crash and burn ? Seems to be a favourite of day traders in US, where shares traded seem to greatly exceed available shares.So $10+ isn't as daft as it seems, but how do you get out quickly ? | corrientes | |
25/6/2018 23:09 | No wonder we see these huge fluctuations with (I think) less than 10 million shares outstanding. Now if the company has any success getting to Phase 3, then it really is to the moon. | corrientes | |
25/6/2018 21:15 | Just under 6M shares traded today: | poppa wobbler | |
05/10/2017 18:03 | Broker saying 'XEN' could reach $10,but any research not in public domain yet. | corrientes | |
04/10/2017 13:27 | Seeking Alpha has no idea why at this point.Movements here are absolutely crazy, but maybe a small fund taking a punt.Hope its not a P&D. | corrientes | |
04/10/2017 13:03 | Hmmmm ..... | poppa wobbler | |
03/1/2017 16:48 | Interest stirring here for what its worth to UK holders ! | corrientes | |
17/11/2016 16:53 | Now we have 9 cents drop to 3.3101 from yesterday's $4.00. This company should be quoted on Noddydaq. | corrientes | |
14/11/2016 16:56 | 51c or 14.53% improvement so far today to $3.47 on 9 shares traded, when the 52 week range is stated as 3.30-29.37 says everything you need to know here,Best to regard the value of this stock as worthless. Mind you, Trump did win the US election, so miracles do happen, but not here I suspect. | corrientes | |
14/11/2016 12:53 | the Circus goes on.. uplist to Nasdaaq yet still cant get calue or trade through my broker TD.. what a shambles this stock is. Anyone else having the same issue? | trotterstrading | |
04/11/2016 10:42 | Agreed Trotters. | smcl | |
04/11/2016 09:46 | Finally.. feels like and eternity.. typical the day they list is the day before the US election.. FFS, you couldn't make it up Held for years will hold for another 12 months to let this play out | trotterstrading | |
01/11/2016 22:20 | Of modest interest for most UK punters I expect, given the previous huge dilution. Still better than a kick in the pants. | corrientes | |
11/10/2016 04:35 | 10/10/2016 Xenetic Biosciences (XBIO) Announces Favorable Data from Third Cohort of ErepoXen Phase 3 in Anemia Xenetic Biosciences, Inc. (OTC: XBIO) announced positive topline data from the third cohort of its Phase 2 dose-escalation study with its lead drug candidate ErepoXen for the treatment of anemia in pre-dialysis chronic kidney disease patients. This trial is being conducted for Xenetic by Novotech (Australia) Pty Ltd. The third cohort of the Phase 2, open label, sequential dose finding study to evaluate the safety, pharmacodynamics (PD) and pharmacokinetics (PK) of multiple doses of ErepoXen was launched in October 2015 and was conducted in Australia and South Africa. As in the previous cohorts, patients in the third cohort of this study received injections of ErepoXen every two weeks until hemoglobin levels reached therapeutic levels. The patients then received injections of ErepoXen every 4 weeks (extended dosing interval) during maintenance for a total trial time of 17 weeks. Professor Simon D Roger M.D., FRACP, Director of Renal Medicine, Gosford Hospital, Australia and Principal Investigator of the study, said, “The results achieved with ErepoXen® in these individuals with chronic kidney disease expand on the initial two cohorts, and, continue to demonstrate a reassuring safety profile. I am very pleased about the potential for ErepoXen® to act as a therapeutic agent to treat these anemic patients and look forward to the continued study of this compound to achieve further results.” The data from the second cohort show that 11 of 12 (91%) of the enrolled patients had an increase in hemoglobin levels over time, and that in 9 of 12 (75%) of the enrolled patients, hemoglobin levels rose into the targeted therapeutic range (10-12 g/dL). The third cohort was designed to achieve a faster rate of rise of hemoglobin than the previous cohorts, but still less than the recommended 1g/dL per 4 weeks. Data from the third cohort showed that 11 of 14 (79%) of the enrolled patients had an increase in hemoglobin levels over time, and that 10 of 14 (71%) of the enrolled patients, hemoglobin levels rose into the therapeutic range of 10-12 g/dL. The cohort average hemoglobin level reached the therapeutic range between weeks 4 and 6 after initiation of therapy. Hemoglobin levels were then maintained within the therapeutic range for the remainder of the 17-week study. This compares favorably with the first two cohorts, which showed an increase in the average hemoglobin levels over the course of the 17-week study. In all three cohorts, ErepoXen® was generally well tolerated and there was only one possibly related significant adverse event in cohort 3. In none of the cohorts has there been an increase the immune response as measured by IgG or IgM antibodies to PSA, EPO or PSA-EPO. Overall the safety profile of ErepoXen to maintain red blood cell production and prevent anemia remains favorable. Initial PK results confirmed the original product serum half-life of greater than 400 hours. “The completion of this third cohort study is a noteworthy step in the development pathway of ErepoXen. We continue to see exciting data being generated and believe ErepoXen has potential to be a promising treatment option for anemic patients,” stated Scott Maguire, CEO. “While the data from this study are positive and maintained the safety profile, we believe that we have not yet reached the most effective clinical dose for these patients. We are therefore continuing this Phase 2 study and look forward to sustained good news. More broadly speaking, the results we are announcing today have increased our confidence in the potential of our patented PolyXen® technology which has significantly changed the biological half-life of epoetin (an injectable form of endogenous erythropoietin) while maintaining its pharmacological activity in humans. We expect that this technology may be applicable to a large variety of therapeutic compounds, not only modifying their biological properties, but also generating new patent exclusivities.” | buywell3 | |
10/10/2016 01:06 | .................... ZIKA and the need for newer and better molecular assays There will be many other diseases affecting babies identified over the coming months OCT 6, 2016 In a new study published today in the New England Journal of Medicine Carlos Pardo together with Beatriz Parra and a consortium of doctors and scientists from Colombia and Johns Hopkins Hospital examined 68 patients from six Colombian hospitals. Of the 68 Guillain-Barré They tested 42 of the patients for Zika virus using sensitive molecular assays, and found that 17 of them (40%) had detectable Zika virus. Guillain-Barré Drs. Pardo and Parra also found evidence of a possible link between GBS and both Zika and dengue virus: 32 out of 37 Guillain-Barré In an editorial accompanying the new study, Jennifer Frontera and Ivan da Silva write that although the new study supports the link between Zika and GBS, confirmatory evidence in more patients will strengthen the (possible) causal association. They warn that “the Zika virus pandemic is just beginning in North America and Africa, and an increase in the incidence of the Guillain-Barré Steven Salzberg is the Bloomberg Distinguished Professor of Biomedical Engineering, Computer Science, and Biostatistics at Johns Hopkins University. | buywell3 | |
14/9/2016 02:03 | .................... Zika vaccine research firm attracts private funding offers after clinching grant 08/09/2016 Private investors are queueing up to fund a small British pharmaceutical company that holds promise of developing the world's first Zika vaccine. Cambridge-based firm Excivion has gained attention since clinching a Government grant worth £500,000 that will help jump-start vaccine development for the mosquito-borne virus. Chief executive and immunologist Peter Laing says he has never seen this kind of interest from private investors during his 22-year career. "I've had people contact me on the website, offering to fund the company. I've never heard of that before, never heard of it in the history of my work in the biotechnology industry," he told the Press Association. Excivion is seeking private backers to keep research going once government funding runs out. The half a million pound grant, issued by the Small Business Research Initiative and Innovate UK, is meant to be spent within 12 months. It is part of the Department of Health's plans to invest up to £10 million in two competitions that would prompt development of vaccines for infectious diseases and technologies. The company is aiming to bring a vaccine to market by 2023, and Excivion staff are working around the clock to develop it. Mr Laing has contracted around 30 scientists across India, the US, Germany and the UK to supplement the company's two-person operation back in Cambridge. This strategy has allowed Mr Laing to recruit the best industry specialists and keep costs down. In mid-August, the company announced a partnership with US-based Nasdaq-listed pharma firm Xenetic Biosciences to develop technologies to deliver the vaccine. Excivion is working with ''micro-encapsulatio "There's a lot of moral pressure to do everything right, and to make sure that you've thought everything through," he said. "It's been been quite stressful actually, because we want to take best advantage of the funding and do right by the British public who ultimately fund this work." Mr Laing and his business partner have put their own money into the company, but he says it is small in comparison. The chief executive is confident Excivion will secure further funding, given the level of interest so far. Mr Laing stopped short of revealing the total number of private offers Excivion has received, but said the company is now eyeing alternative fundraising methods. "In fact we're even considering setting up a parallel charity which would ensure that 100% of those funds could be applied to research and development." There are plans to license the potential Zika vaccine "quite early" to a larger pharmaceutical company that would commit to bringing the product to market. Multiple licenses could be issued in a bid to keep costs low for the countries that need the Zika vaccine most. However, the chief executive made clear that Excivion is not looking for a buy-out. "I want to be a larger company but I don't want to sell the company. I want the company to be in Britain, creating employment, and developing new vaccines." | buywell3 |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions